A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations.
Saved in:
| Title: | A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations. |
|---|---|
| Authors: | Jung M; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea., Park SH; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea., Kim H; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea., Kim Y; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea., Yun UJ; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea., Hwang J; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea., Kim HS; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea., Lee CK; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea., Kim H; Department of Pathology, Yonsei University College of Medicine, Seoul, Korea., Lee C; Department of Pathology, Yonsei University College of Medicine, Seoul, Korea., Koo DH; Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea., Jeung HC; Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea., Zang DY; Division of Hematology-Oncology, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang, Korea., Song EK; Division of Oncology-Hematology, Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Korea., Rha SY; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea.; Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea. |
| Source: | Cancer research and treatment [Cancer Res Treat] 2026 May 04. Date of Electronic Publication: 2026 May 04. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Korean Cancer Association Country of Publication: Korea (South) NLM ID: 101155137 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2005-9256 (Electronic) Linking ISSN: 15982998 NLM ISO Abbreviation: Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
